Abstract
Juvenile idiopathic Arthritis (JIA) is a common rheumatic disorder in children that can cause multiple systems to be affected simultaneously, leading to severe clinical symptoms and a high mortality rate in those with pulmonary involvement. Pleurisy is the most common manifestation of pulmonary involvement. At the same time, other conditions, such as pneumonia, interstitial lung disease, occlusive bronchiectasis, and alveolar protein deposition, have been increasingly reported in recent years. This review aims to provide an overview of the clinical manifestations of JIA lung damage and the current treatment options to assist in identifying and treating JIA lung involvement.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Juvenile idiopathic arthritis is a heterogeneous group of inflammatory diseases, and the incidence of lung damage in JIA patients has been increasing. Therefore, it is essential for healthcare providers to be aware of the potential clinical manifestations of lung damage in JIA, so that early recognition and treatment can be initiated, thus improving the prognosis of these children. |
JIA-associated lung damage can present with a variety of symptoms, including pleurisy (with or without pleural effusion), diffuse lung diseases (e.g., lipoid pneumonia, pulmonary interstitial lesions with alveolar proteinosis-like changes, pulmonary hemosiderosis, and pulmonary hypertension), and secondary pulmonary infections particularly sJIA and pJIA. Interstitial lung disease is the predominant form of this damage, and it can be severe and even fatal. |
The treatment of lung damage related to JIA is not uniform and there is no unified guideline. Various biological agents, small molecule targeted agents, and plasma exchange have been studied for the treatment of JIA-associated lung damage through clinical studies and individual case reports, but more research is needed. Moreover, controlling the primary disease activity is essential for the successful treatment of lung damage. |
The cause of lung damage associated with JIA is not well understood, however, genetic, immune, and infectious elements may all be involved in its development. Immune components are especially significant, as increased production of cytokines such as IL-6, IL-18, and IFN-γ can lead to alveolar macrophage dysfunction and ultimately cause lung damage. Uncovering the underlying pathogenesis of lung damage associated with JIA, in particular sJIA combined with pulmonary interstitial lesions, could facilitate more precise treatments, although its origins remain unclear. |
Introduction
Juvenile idiopathic arthritis (JIA) is a group of heterogeneous inflammatory diseases that are classified by the International League Against Rheumatism (ILAR) into seven subtypes according to their clinical manifestations and laboratory tests, namely, systemic, rheumatoid factor rheumatoid factor (RF) + polyarticular, RF- polyarticular, oligoarticular, enthesitis-associated arthritis, psoriatic arthritis, and undifferentiated arthritis [1]. A combination of genetic and environmental factors leads to immune tolerance and inflammatory dysregulation, producing a chronic inflammatory response, recruitment of inflammatory cells, and production of large amounts of cytokines, resulting in systemic symptoms and multi-organ tissue damage [2]. The cause of lung damage associated with JIA is not well understood, however, genetic, immune, and infectious elements may all be involved in its development. Immune components are especially significant, as increased production of cytokines such as interleukin (IL)-6, IL-18 and interferon (IFN)-γ can lead to alveolar macrophage dysfunction and ultimately cause lung damage [3, 8]. Although the prevalence of lung damage in JIA patients is low, it has been increasing in recent years, with interstitial lung disease (ILD) predominating, with severe clinical manifestations and a high mortality rate [3], which has attracted widespread academic attention. In addition, lung damage can be manifested as pleurisy (with or without pleural effusion), secondary lung infection, diffuse alveolar hemorrhage, pulmonary hypertension, etc. The type of combined lung damage varies among different subtypes of JIA, with systemic juvenile idiopathic arthritis (sJIA) and RF + polyarticular juvenile idiopathic arthritis (pJIA) types being prone to combined lung damage, and the clinical manifestations vary greatly [3, 8]. They range from pleural effusion with no apparent symptoms to life-threatening diffuse alveolar hemorrhage. The early recognition and treatment of JIA lung damage directly affects the prognosis of patients. This article provides a comprehensive overview of the various clinical manifestations of JIA that are associated with lung damage, with the intention of aiding early identification of such patients in the general public. Additionally, it reviews the available treatments for the different types of lung damage, since there is a scarcity of large clinical studies in this regard, in the hope of inspiring readers to explore effective treatment options and enhance the prognosis of children with JIA and lung damage.
Methods
We conducted a systematic review and meta-analysis of clinical studies, clinical trials, reviews, and meta-analyses in Chinese and English published between January 1, 1980, and December 1, 2022. The search terms used to identify relevant studies included "juvenile idiopathic arthritis", "systemic juvenile idiopathic arthritis", "rheumatoid factor", "polyarticular juvenile idiopathic arthritis", "pulmonary", "pleural", "interstitial lung disease", and "pulmonary infection". We searched PubMed, Web of Science, the Cochrane Library, and CNKI to identify relevant studies. Adhering to previously published guidelines for narrative reviews and PRISMA guidelines [65, 66], we conducted a comprehensive review of the literature. This study did not include any experiments involving human or animal participants (Fig. 1).
Results and Discussion
Pleural Involvement
Pleurisy is the most common pulmonary manifestation of JIA. It is more common in sJIA, which is included as one of the diagnostic criterium for sJIA in both the ILAR and the new 2019 JIA diagnostic criteria consensus from the Pediatric Rheumatology International Trials Organization (PRINTO) [4]. The incidence of pleurisy varies among ethnic groups. The incidence of pleurisy has been reported to be about 3.6% in sJIA in Italy [5], 1.9% in North America and Canada [6], and 1.2% in France [7], while the incidence of pleurisy in various subtypes of JIA in China is about 4.4% [8]. Macrophage activation syndrome (MAS) is a potentially life-threatening complication of JIA, which is complicated by the combination of MAS in about 10% of sJIA patients, and the prevalence of subclinical forms is as high as 30% and 40% [9]. A multicenter study in China found that sJIA patients with combined MAS were more likely to present with pleurisy, with a rate of 7.5% [10]. JIA-associated pleurisy mostly has no obvious clinical symptoms, but some may present with chest pain, dry cough, fever, and in severe cases, respiratory distress. Imaging examination reveals unilateral or bilateral pleural effusion and pleural thickening as aseptic exudate with increased lymphocytosis, low glucose, elevated lactate dehydrogenase and protein [11], with attention to exclude infection, pulmonary embolism, and heart failure.
Treatment for pleurisy depends on the severity of the condition and the amount of pleural effusion. No specific treatment may be necessary for those with mild symptoms, and pleurisy should resolve itself when the primary disease is controlled. Those with chest pain may be prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) as recommended by the American College of Rheumatology (ACR) [12]. Anjali Sura et al. observed that those with plasmacytosis were less likely to use this approach [13]. For those with moderate-to-severe pleurisy, high-dose methylprednisolone shock (10–30 mg/kg day, up to 1–2 g/day for 1–3 days) followed by oral glucocorticoid therapy (up to 1–2 mg/kg day, up to 60 mg/day) may be advised [14]. Also, thoracentesis aspiration or closed chest cavity drainage may be considered for those with significant compression symptoms.
Diffuse Lung Disease
Diffuse lung disease (DLD) or diffuse parenchymal lung disease (DPLD), formerly known as ILD, is a broad term for a variety of heterogeneous diseases characterized by pathological changes in the distal lung units and impaired gas exchange [15]. In 2007, the Children’s Interstitial Lung Disease (chILD) proposed a classification system for DPLD in children under 2 years of age. In 2013, an extended classification was proposed, extending to children 18 years of age. This classification system is based on histological differences. It includes diffuse developmental and growth abnormalities, surface active substance abnormalities (such as pulmonary alveolar protein deposition, PAP), interstitial pneumonia, lymphoproliferative disorders, other typed of diffuse lung disease (such as iron-containing heme deposits and systemic disease-associated ILD), diseases resembling diffuse lung disease (such as small airway lesions like obliterative bronchiolitis (BO) and vascular lesions like pulmonary arterial hypertension (PAH), and specific types of disease of unknown etiology [16]. sJIA is associated with a combination of DLD, including interstitial pneumonia, alveolar protein deposition, iron-containing heme deposits, and pulmonary hypertension. RF + pJIA is less common and resembles adult rheumatoid arthritis, with the potential for rheumatoid nodules in addition to the manifestations mentioned above [25, 26, 52]. The typical manifestations of DLD and the possible treatment options for each subtype are outlined below. Table 1 outlines the typical clinical presentation of DLD and the primary treatment approaches for sJIA and RF + pJIA patients.
sJIA with DLD
It was observed that before 2010, sJIA combined with DLD was an extremely uncommon occurrence. Only a few cases had been reported [17, 18], exhibiting symptoms such as cough, dyspnea, and shortness of breath after physical activity. Lung high-resolution CT (HRCT) scans revealed ground-glass-like turbidity, eventually progressing to lobular septal thickening and fibrotic changes. However, since then, the number of cases of sJIA combined with DLD has increased. While some scholars have suggested that the use of biologics may be a contributing factor, it is unclear what is causing the increase in cases of sJIA combined with DLD. In 2011, a study involving 25 cases of sJIA combined with DLD revealed that 80% of patients were diagnosed after 2004, with 64% having PAH, 20% having PAP, and 28% having ILD. Moreover, the study highlighted a high mortality rate of about 68%, garnering the attention of the rheumatology community [19].
Lipoid pneumonia
Lipoid pneumonia (LP) is a rare form of DLD divided into two categories: endogenous and exogenous. Exogenous lipoid pneumonia (ELP) is linked to inhalation of mineral oil, gastroesophageal reflux, etc. Endogenous lipoid pneumonia, also known as cholesterol pneumonia, is predominantly obstructive and is caused by chronic pulmonary infections or abnormal lipid metabolism resulting in intra-alveolar lipid accumulation [20]. It is a scarce condition in sJIA, with only two cases reported.
In 2001, Finland reported a case of refractory sJIA accompanied by lipoid pneumonia [21], which was characterized by a cough, dyspnea, detectable dry rales on pulmonary examination, presence of secondary mild PAH, nodular lattice-like changes in the central lobular region and pulmonary fibrosis on lung CT, restrictive lung disease on lung function, and lung biopsy suggesting cholesterol granuloma-like pathological changes in the interstitial and alveolar lung. Ultimately, the patient succumbed to respiratory failure due to a worsening lung infection. In 2010, Toronto reported a 21-year-old patient with sJIA who presented with nocturnal paroxysmal cough and progressive exertional dyspnea [22]. Pulmonary CT revealed thickened lobular septa and ground-glass turbidity at the base of the lung, pulmonary function was restrictive ventilation, bronchial lavage fluid was dominated by foamy macrophages containing large fatty vesicles, and pulmonary pathology suggested small airways. The final diagnosis of endogenous lipid-like pneumonia was made, with gastroesophageal reflux in both cases.
Treatment options for lipoid pneumonia are limited, but clinical improvement has been reported after using whole lung bronchoscopy lavage, hormones, and tumor necrosis factor-alpha antagonists. In some cases, lung transplantation has been used to treat secondary lung infection [22, 23]. Additionally, intensive immunosuppressive therapy, such as methylprednisolone shock and cyclophosphamide arthritis were used. Controlling the underlying disease activity may also be beneficial in managing lipoid pneumonia [24].
Highly Lethal Lung Disease-Alveolar Protein Deposition-like Features
Pulmonary alveolar proteinosis (PAP) is a DLD associated with sJIA since 2013. It is characterized by an accumulation of alveolar surface active substances and dysfunction of alveolar macrophages, leading to progressive dyspnea, secondary lung infections, and pulmonary fibrosis. This disorder can be divided into primary and secondary categories, with primary PAP caused by genetic or autoimmune disruption of granulocyte–macrophage colony-stimulating factor (GM-CSF) signaling and secondary PAP primarily caused by impaired macrophage numbers or function [25]. Since 2015, sJIA combined with a highly lethal lung disease presenting with PAP-like pathological changes has been widely reported, with a prevalence of up to 6.8%. In 2019, a prospective cohort study from a single center in Cincinnati, OH, USA, summarized the clinical features of 18 patients [26]. A retrospective study of 61 cases reported by the Children’s Arthritis and Rheumatism Trial Alliance (CARRA) in the USA identified risk factors, including age at diagnosis < 2 years, recurrent MAS, high incidence of adverse reactions to biological agents (IL-1 or IL-6 inhibitors), and significantly elevated serum IL-18 levels. The trisomy 21 ratios were higher than in the sJIA cohort.
The majority of patients with the sJIA-LD present with an insidious onset and mild clinical manifestations, such as mild shortness of breath and pestilential fingers, as the primary manifestation. In addition, more than half of patients have an erythematous rash with pruritus, 37% eosinophilia, and a few have unexplained abdominal pain. Allergic reactions to biological agents are significantly more common in sJIA-LD, up to 38%. Laboratory tests reveal an increase in ferritin levels and a decrease in lymphocytes (absolute counts < 60% of the lower limit of normal). Krebs Von den Lungen-6 (KL-6) can be used as an effective biomarker for sJIA-LD [67]. HRCT scans show characteristic changes, including septal thickening, paving stone sign, peripheral solidity, solidity around the bronchovesicular wall, ground-glass turbidity, and enlarged lymph nodes. The most common of these is septal thickening involving multiple perihilar lobes with or without ground-glass shadowing, typically affecting the lower lung region, anterior upper lobe, perihilar or peri-mediastinal regions, and occurring in roughly 60% of cases. Additionally, pulmonary ultrasonography has been used to diagnose sJIA-LD, displaying focal or diffuse irregular pleural thickening with scattered or synthetic B-lines and subpleural solidity [27]. Pulmonary function tests are not currently available to detect signs of sJIA-LD. However, a 6-min walk test or a pulmonary function test for carbon monoxide lung diffusion capacity may be beneficial. Lung biopsies performed on patients with sJIA-LD revealed a combination of PAP and ELP with extensive lymphoplasmacytic infiltration. In contrast to autoimmune or hereditary PAP, sJIA-LD patients exhibited an increased presence of foamy macrophages, cholesterol lacunae, inflammation, and fibrosis. Bronchial lavage (BAL) did not display diagnostic PAP features but was predominantly composed of macrophages with high levels of IL-18 and interferon-γ-induced chemokines (CXCL) 9 and CXCL10; Lung tissue transcription analysis indicated a trend of upregulation of IFN II and T cell activation network.
The 5-year survival rate for this highly lethal form of sJIA-LD is only 42%, and the best treatment option is currently unknown. There is a history of biological exposure in these patients, though it is not clear whether it is drug-related. Schulert et al. reported that all patients in their cohort were treated with biologics, and 50% saw stable and progressive improvement. In Thailand, one patient with sJIA-LD was treated with the IL -6 inhibitor tocilizumab, resulting in disease control [28]. Additionally, the upregulation of transcription of genes related to the IFNγ pathway and T-cell activation pathway in BAL fluid and lung tissue has led to the attempted application of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib to block IFNγ signaling therapy with good efficacy [29]. The safety and efficacy of JAK inhibitors for sJIA-LD should be further studied. Other targeted T-cell drugs, such as cyclosporine and mycophenolate mofetil, may also be considered to control LD [30]. In some cases, LD has been associated with drug reaction with eosinophilia and systemic symptoms (DReSS), which is caused by severe delayed hypersensitivity reactions, hyperinflammatory state of the organism, and whole-blood cytopenia [31, 32]. Early discontinuation of the suspected drug is necessary to control disease progression. Sato et al. reported the successful treatment of a patient with sJIA-LD combined with MAS via plasma exchange [33]. Despite this, the exact pathogenesis of the highly lethal lung disease in patients with sJIA remains unknown. Further research is needed to uncover the pathogenesis and determine the best clinical treatment.
Hematoxylin Deposition
Pulmonary hemosiderosis (PH) is a rare form of DLD characterized by recurrent episodes of diffuse alveolar hemorrhage (DAH). This leads to large amounts of iron accumulation in alveolar macrophages, resulting in cellular necrosis, tissue remodeling with pulmonary fibrosis, and the stimulation of ferritin production by macrophages, leading to hyperferricemia [34]. The age of onset of PH ranges from the neonatal period to adulthood, with a prevalence of approximately 0.24–1.23 per million person-years and a mortality rate of up to 50%. Clinical manifestations of PH include recurrent dyspnea, cough, fever, and varying degrees of anemia, with hemoptysis present in about half of the patients [35]. Chest radiographs may show pulmonary edema and patchy shadows. In contrast, HRCT may show diffuse or patchy ground-glass opacity, as well as the “paving stone sign” and lobular thickening due to pulmonary ferritin deposition. Bronchial lavage fluid is hemorrhagic and is dominated by alveolar macrophages with the presence of hemosiderin [36]. There have been no cohort studies on sJIA-PH, and only two cases have been reported on a case-by-case basis, one with recurrent MAS and one with combined trisomy 21 [37, 38]. It is essential to be aware of the potential for PH in patients with sJIA presenting with recurrent MAS, as dyspnea, iron deficiency anemia, and diffuse changes suggested by lung imaging may be present. It is hypothesized that sJIA-PH is associated with highly elevated serum ferritin levels, although this does not represent the level of iron stores in the alveoli [39].
Treatment of PH typically involves the use of glucocorticoids either alone or in combination with other immunosuppressants. In acute alveolar hemorrhage accompanied by respiratory failure, vital signs can be maintained through mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and high-dose methylprednisolone shock therapy [34]. Liposteroid, a lipid-based dexamethasone palmitate with potent anti-inflammatory properties, has been developed and studied in Japan and used to treat rheumatic diseases in conjunction with MAS [40]. This drug is absorbed by activated pulmonary macrophages, thus preventing the breakdown of heme and hemosiderin accumulation, thus treating PH [41]. However, it has yet to be applied to the treatment of sJIA.
Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a condition characterized by an elevated pulmonary artery systemic pressure (PAP) of more than 20 mmHg and an increased pulmonary vascular resistance (PVR) of more than 3 Wood units, with normal pulmonary venous pressure (pulmonary wedge pressure < 15 mmHg) [42]. A cohort study by Kimura et al. found that 64% (16/25 cases) of patients with sJIA had pulmonary hypertension with pulmonary complications. Still, only 25% had interstitial lung disease or alveolar protein deposition manifestations. Furthermore, the disease activity was higher in patients with sJIA (including combined MAS) when PAH with pulmonary complications was diagnosed, suggesting that the severity of systemic inflammation plays a vital role in the pathogenesis of PAH [19, 43]. Symptoms of severe PAH may include exertional dyspnea, fatigue, syncope, cyanosis, chest pain, and in rare cases, heart failure [44]. Physical examination may reveal a separation of second heart sound separation and pulmonary valve murmur, while echocardiography is a sensitive tool for identifying PAH. Physical examination may reveal a separation of the second heart sound and pulmonary valve murmur, while echocardiography is a sensitive tool for identifying PAH. Cardiac catheterization is the gold standard for diagnosis, and other tests such as cardiac magnetic resonance imaging (MRI), 6-min walk test, chest computed tomography (CT), and pulmonary function can also be used to assess cardiopulmonary function.
The primary treatment for sJIA in combination with PAH is to manage the active state of the primary disease and provide medical support such as oxygen therapy, cardiac strengthening, diuresis, and anticoagulation. Targeted therapies for PAH have been studied, with the only clinical trial data relevant to children for phosphodiesterase inhibitor type 5 -sildenafil [45]. A case study by Luciana et al. reported the use of IL-1 inhibitor canakinumab to treat a patient with sJIA combined with MAS and severe pulmonary hypertension [46], offering a potential new treatment option for patients with MAS and PAH-related sJIA.
pJIA with DLD
RF + pJIA is analogous to adult rheumatoid arthritis, and rheumatoid nodules, as well as interstitial lung disease, and can be seen in association with DLD, which may present as interstitial pneumonia, diffuse pulmonary hemorrhage, and mechanized pneumonia due to fine occlusive bronchitis [47, 48].
Pulmonary rheumatoid nodules are a rare extra-articular manifestation of rheumatoid arthritis, with a prevalence ranging from 0.4 to 32% [49]. Generally, they do not cause any clinical symptoms; however, some individuals may experience cough, usually in the interlobular septum or subpleural lung areas [50]. Around half of these nodules can later form cavities or lead to pleural effusion and spontaneous pneumothorax [51]. In children with RF + pJIA, the nodules are similar to those of adults, and methotrexate treatment may accelerate their appearance, necessitating dynamic monitoring [52]. The IL-6 inhibitor tocilizumab has been found to improve pulmonary rheumatoid nodules in adult patients [53], and its efficacy in patients with pJIA needs further study.
Patients with RF + pJIA combined with ILD typically present with no obvious respiratory symptoms, patchy ground-glass changes on high-resolution CT of the lungs, and no specific changes in bronchial lavage fluid. Elevated salivated glycocalyx antigen KL-6 has been reported in isolated cases [54]. Maruyama et al. reported that KL-6 levels decreased to normal and intrapulmonary lesions improved significantly after the application of the IL-6 inhibitor tocilizumab for pJIA, which was attributed to the inhibition of IL-6 production and reduction of its pro-fibrotic effect on lung fibroblasts. However, drug-induced lung injury must be considered during the application, as one case of acute interstitial lung disease after applying tocilizumab for pJIA was reported in 2021 [55]. Additionally, patients with RF + pJIA in combination with ILD should be monitored for auto-inflammatory diseases, such as mutations in the COPα gene, which can lead to excessive production of type I interferon and present as RF + recurrent arthritis and interstitial lung lesions [56, 57]. Similarly, STING-associated vasculopathy with onset in infancy (SAVI) has been reported to have early onset RF + polyarthritis combined with an ILD clinical phenotype [58]. Therefore, genetic testing should be conducted to exclude auto-inflammatory diseases in RF + polyarthritis combined with ILD with a positive family history.
Secondary Pulmonary Infections
A study involving 365 patients with JIA revealed that a significant number (24%) had developed nosocomial infections, particularly bacterial pneumonia, a rate higher than that in control children [59]. A comparative cohort study found that procalcitonin (PCT) could be used as a marker to differentiate between active JIA and bacterial infection [60]. Additionally, Mycoplasma pneumonia infection was observed in 21.2% of JIA patients, particularly those with oligoarticular JIA, and was associated with an elevation in serum IgE levels [61]. These high-rated respiratory tract infections in JIA patients may be attributed to the dysfunctional immune function of the body, the low antimicrobial activity of alveolar macrophages, and the use of immunosuppressive agents in JIA patients.
Studies from Brazilian and Portuguese registries have revealed that approximately 10.6% of children are infected with tuberculosis [62]. Therefore, it is essential to actively exclude TB infection when children with JIA present with symptoms such as hypothermia, wasting, and night sweats. The 2021 ACR guidelines recommend screening for Mycobacterium tuberculosis before the initiation of biologic-based disease-modifying anti-rheumatic drugs (DMARDs) and after treatment, if there is suspected exposure to Mycobacterium tuberculosis [12]. A study by Hügle et al. using the German Center for Pediatric and Young Adult Rheumatology database found no significant disease activity in JIA patients with SARS-CoV-2 infection. Additionally, Haşlak et al. compared seropositivity rates between JIA patients and healthy controls with asymptomatic SARS-CoV-2 infection without substantial differences. However, SARS-CoV-2 infection-induced cytokine changes may lead to outbreaks of JIA in more susceptible populations. Therefore, further research is needed to understand better the potential relationship between necrobiosis and JIA in children with JIA and pneumoconiosis to determine the long-term prognosis after infection [63, 64].
Conclusions
The incidence of pulmonary damage in JIA has been increasing recently, with manifestations ranging from asymptomatic pleural effusions to life-threatening acute interstitial lung disease and diffuse alveolar hemorrhage. Medical professionals must use imaging techniques, pulmonary function tests, fiberoptic bronchoscopy, alveolar lavage, and lung biopsy to diagnose such conditions. Therefore, clinicians need to be aware of the risk factors and clinical manifestations of various lung damage in JIA so that they can identify them early and adjust their strategies accordingly to reduce the incidence and associated morbidity and mortality. HRCT should be a standard practice for JIA patients to evaluate their lung conditions. Those with high-risk factors, including age at onset below 2 years, recurrent MAS, high incidence of adverse reactions to biological agents (IL-1 or IL-6 inhibitors), significantly elevated serum IL-18 levels, and positive RF, should have their lung imaging monitored every 3–6 months during treatment, regardless of respiratory symptoms. Pulmonary function tests should be conducted to detect any potential lung damage, if available. Furthermore, a multidisciplinary approach involving specialists in respiratory medicine, imaging, and pathological blood is essential for successful diagnosis and treatment [68].
References
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatolog. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
Martini A, Lovell DJ, Albani S, Brunner HI, Hyrich KL, Thompson SD, Ruperto N. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8(1):5. https://doi.org/10.1038/s41572-021-00332-8.
Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, Canna S, Schulert G, Deterding R, Xu J, Leung AN, Bouzoubaa L, Abulaban K, Baszis K, Behrens EM, Birmingham J, Casey A, Cidon M, Cron RQ, Childhood Arthritis and Rheumatology Research Alliance Registry Investigators. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12):1722–31. https://doi.org/10.1136/annrheumdis-2019-216040.
Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N, Pediatric Rheumatology International Trials Organization (PRINTO). Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–7. https://doi.org/10.3899/jrheum.180168.
Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, Naddei R, Di Cola I, Di Muzio C, Berardicurti O, Iacono D, Pantano I, Rozza G, Rossi S, De Stefano L, Balduzzi S, Vitale A, Caso F, Costa L, Prete M, Ravelli A. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Rheumatology (Oxford, England). 2022;61(10):4124–9. https://doi.org/10.1093/rheumatology/keac027.
Janow G, Schanberg LE, Setoguchi S, et al. The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013. J Rheumatol. 2016;43(8):1618. https://doi.org/10.3899/jrheum.150997.C1.
Felix A, Delion F, Suzon B, Pallara-Sirven S, Elenga N, Quartier P, Louis-Sidney F, Dramé M, Hatchuel Y. Systemic juvenile idiopathic arthritis in French Afro-Caribbean children, a retrospective cohort study. Pediatric Rheumatol Online J. 2022;20(1):98. https://doi.org/10.1186/s12969-022-00766-8.
Hu Y, Lu MP, Teng LP, Guo L. Zou LX Zhongguo dang dai er ke za zhi. Chinese J Contemp Pediat. 2014;16(8):783–6.
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–68. https://doi.org/10.1038/nrrheum.2015.179.
Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS, Xiao JH, Yu HG, Guo L, Xu YP, Lu MP. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China. WJP. 2020;16(1):89–98. https://doi.org/10.1007/s12519-019-00256-0.
Shiel WC Jr, Prete PE. Pleuropulmonary manifestations of rheumatoid arthritis. Semin Arthritis Rheum. 1984;13(3):235–43. https://doi.org/10.1016/0049-0172(84)90027-1.
Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, Becker ML, Cron RQ, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Kimura Y, Lee T, Murphy K, Nigrovic PA, Ombrello MJ, Rabinovich CE, Tesher M, Twilt M, Reston JT. 2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol (Hoboken NJ). 2022;74(4):553–69. https://doi.org/10.1002/art.42037.
Sura A, Failing C, Sturza J, Stannard J, Riebschleger M. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2018;16(1):2. https://doi.org/10.1186/s12969-017-0219-4.
Batu ED. Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int. 2019;39(1):13–27. https://doi.org/10.1007/s00296-018-4168-0.
Vece TJ, Young LR. Update on diffuse lung disease in children. Chest. 2016;149(3):836–45. https://doi.org/10.1378/chest.15-1986.
Rice A, Tran-Dang MA, Bush A, Nicholson AG. Diffuse lung disease in infancy and childhood: expanding the chILD classification. Histopathology. 2013;63(6):743–55. https://doi.org/10.1111/his.12185.
Mubashir E, Ahmed MM, Hayat S, Heldmann M, Berney SM. Pulmonary hypertension in a patient with adult-onset Stills disease. Clin Rheumatol. 2007;26(8):1359–61. https://doi.org/10.1007/s10067-006-0382-3.
Weiss JE, Lee T, Rabinovich CE, Wallace CA, Oliveira SK, Onel K, Anton J, Kimura Y. Life-threatening pulmonary hypertension (PH) and alveolar proteinosis (AP) in systemic JIA (SJIA). Arthritis Rheum. 2008;58(9S):S257–8.
Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, Rabinovich E, Riebschleger M, Antón J, Blier PR, Gerloni V, Hazen MM, Kessler E, Onel K, Passo MH, Rennebohm RM, Wallace CA, Woo P, Wulffraat N, Childhood Arthritis Rheumatology Research Alliance Carra Net Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(5):745–52. https://doi.org/10.1002/acr.21889.
Chieng HC, Ibrahim A, Chong WH, Freed H, Fabian T, Saha B, Foulke L, Chopra A. Lipoid pneumonia. Am J Med Sci. 2022;363(5):452–5. https://doi.org/10.1016/j.amjms.2022.01.019.
Schultz R, Mattila J, Gappa M, Verronen P. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA). Pediatr Pulmonol. 2001;32(5):397–402. https://doi.org/10.1002/ppul.1149.
Leber A, Carette S, Chapman KR, Hwang DM, Singer LG, Marras TK. A 21-year-old man with systemic-onset juvenile rheumatoid arthritis, cough and progressive dyspnea. Can Respir J. 2010;17(3):e42–4. https://doi.org/10.1155/2010/810860.
Berghaus TM, Haeckel T, Wagner T, von Scheidt W, Schwaiblmair MG. Endogenous lipoid pneumonia associated with primary sclerosing cholangitis. Lancet (London, England). 2007;369(9567):1140. https://doi.org/10.1016/S0140-6736(07)60530-3.
Morita H, Arai S, Kurasawa K, Okada H, Tanaka A, Yamazaki R, Owada T, Maezawa R. Intensive immunosuppressive therapy for endogenous lipoid pneumonia associated with rheumatoid arthritis. Mod Rheumatol. 2018;28(6):1044–8. https://doi.org/10.1080/14397595.2016.1193270.
Trapnell BC, Nakata K, Bonella F, Campo I, Griese M, Hamilton J, Wang T, Morgan C, Cottin V, McCarthy C. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019;5(1):16. https://doi.org/10.1038/s41572-019-0066-3.
Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol (Hoboken NJ). 2019;71(11):1943–54. https://doi.org/10.1002/art.41073.
Vega-Fernandez P, Ting TV, Mar DA, Schapiro AH, Deluna MD, Saper VE, Grom AA, Schulert GS, Fairchild RM. Lung ultrasound in children with systemic juvenile idiopathic arthritis-associated interstitial lung disease. Arthritis Care Res. 2022. https://doi.org/10.1002/acr.24957. Advance online publication.
Sukharomana M, Udomittipong K, Ruangchira-Urai R, Charuvanij S (2022) Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment. Asian Pacific J Allergy Immunol 40(2):172–176. https://doi.org/10.12932/AP-050819-0616
Bader-Meunier B, Hadchouel A, Berteloot L, Polivka L, Béziat V, Casanova JL, Lévy R. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report. Ann Rheumatic Dis. 2022;81(2): e20. https://doi.org/10.1136/annrheumdis-2020-216983.
Ambler WG, Nanda K, Onel KB, Shenoi S. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann Med. 2022;54(1):1839–50. https://doi.org/10.1080/07853890.2022.2095431.
Binstadt BA, Nigrovic PA. The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol (Hoboken NJ). 2022;74(7):1122–31. https://doi.org/10.1002/art.42137.
Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug reaction with eosinophilia and systemic symptoms (DReSS): How far have we come? Am J Clin Dermatol. 2019;20(2):217–36. https://doi.org/10.1007/s40257-018-00416-4.
Sato S, Hosokawa T, Kawashima H. Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease. Ann Rheumatic Dis. 2022;81(4): e61. https://doi.org/10.1136/annrheumdis-2020-217390.
Saha BK. Idiopathic pulmonary hemosiderosis: A state of the art review. Respiratory Med. 2021;176:106234. https://doi.org/10.1016/j.rmed.2020.106234.
Bakalli I, Kota L, Sala D, Celaj E, Kola E, Lluka R, Sallabanda S. Idiopathic pulmonary hemosiderosis - a diagnostic challenge. Ital J Pediatr. 2014;40:35. https://doi.org/10.1186/1824-7288-40-35.
Zhang Y, Luo F, Wang N, Song Y, Tao Y. Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients. J Int Med Res. 2019;47(1):293–302. https://doi.org/10.1177/0300060518800652.
Barut K, Sahin S, Adrovic A, Sen V, Kasapcopur O. Idiopathic pulmonary hemosiderosis in a child with recurrent macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis. Case Rep Pediatrics. 2017;2017:5693501. https://doi.org/10.1155/2017/5693501.
Bloom JL, Frank B, Weinman JP, Galambos C, O’Leary ST, Liptzin DR, Fuhlbrigge RC. Diffuse alveolar hemorrhage in children with trisomy 21. Pediatr Rheumatol Online J. 2021;19(1):114. https://doi.org/10.1186/s12969-021-00592-4.
Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J. 2004;24(1):162–70.
Wakiguchi H, Ohga S. Nihon Rinsho Men’eki Gakkai kaishi. Japanese J Clin Immunol. 2016;39(3):190–6. https://doi.org/10.2177/jsci.39.190.
Doi T, Ohga S, Ishimura M, Takada H, Ishii K, Ihara K, Nagai H, Hara T. Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur J Pediatr. 2013;172(11):1475–81. https://doi.org/10.1007/s00431-013-2065-9.
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916. https://doi.org/10.1183/13993003.01916-2018.
Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/Paediatric Rheumatology international trials organisation collaborative initiative. Ann Rheumatic Dis. 2016;75(3):481–9. https://doi.org/10.1136/annrheumdis-2015-208982.
Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (London, England). 2012;379(9815):537–46. https://doi.org/10.1016/S0140-6736(11)61621-8.
Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD, STARTS-2 Investigators. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914–23. https://doi.org/10.1161/CIRCULATIONAHA.113.005698.
Paim LB, Landim MLL, Firmino SL, Monteiro CMBE, Cordeiro LR, de Araujo FG, de Carvalho JF. Canakinumab for pulmonary artery hypertension and macrophage activation syndrome associated with uncontrolled systemic juvenile idiopathic arthritis. Indian J Pediatr. 2021;88(6):608–9. https://doi.org/10.1007/s12098-021-03734-4.
Sohn DI, Laborde HA, Bellotti M, Seijo L. Juvenile rheumatoid arthritis and bronchiolitis obliterans organized pneumonia. Clin Rheumatol. 2007;26(2):247–50. https://doi.org/10.1007/s10067-005-0126-9.
Watanabe E, Diniz LR, da Mota LM, Barros SM, de Carvalho JF. Pulmonary capillaritis leading to alveolar hemorrhage in a juvenile idiopathic arthritis patient: first description. Rheumatol Int. 2012;32(6):1855–7. https://doi.org/10.1007/s00296-011-2035-3.
Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis. 1985;131(5):770–7. https://doi.org/10.1164/arrd.1985.131.5.770.
Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respiratory Rev. 2015;24(135):1–16. https://doi.org/10.1183/09059180.00008014.
Sagdeo P, Gattimallanahali Y, Kakade G, Canchi B. Rheumatoid lung nodule. BMJ Case Reports. 2015. https://doi.org/10.1136/bcr-2015-213083.
Muzaffer MA, Schneider R, Cameron BJ, Silverman ED, Laxer RM. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1996;128(5 Pt 1):698–700. https://doi.org/10.1016/s0022-3476(96)80139-9.
Talotta R, Atzeni F, Batticciotto A, Ditto MC, Gerardi MC, Sarzi-Puttini P. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. J Med Case Reports. 2018;12(1):154. https://doi.org/10.1186/s13256-018-1687-y.
Maruyama Y, Shigemura T, Kobayashi N, Nakazawa Y. Efficacy of tocilizumab for interstitial lung disease associated with polyarticular juvenile idiopathic arthritis. Pediatrics Int. 2022;64(1): e14737. https://doi.org/10.1111/ped.14737.
Sugihara K, Wakiya R, Shimada H, Kato M, Kameda T, Nakashima S, Mansour MMF, Ushio Y, Kadowaki N, Dobashi H. Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report. Allergy Asthma Clin Immunol. 2021;17(1):90. https://doi.org/10.1186/s13223-021-00594-7.
Basile P, Gortani G, Taddio A, Pastore S, Corona F, Tesser A, Barbi E, Tommasini A. A toddler with an unusually severe polyarticular arthritis and a lung involvement: a case report. BMC Pediatr. 2022;22(1):639. https://doi.org/10.1186/s12887-022-03716-1.
Krutzke S, Rietschel C, Horneff G. Baricitinib in therapy of COPA syndrome in a 15-year-old girl. Eur J Rheumatol. 2019;7(1):1–4. https://doi.org/10.5152/eurjrheum.2019.18177.
Clarke SLN, Robertson L, Rice GI, Seabra L, Hilliard TN, Crow YJ, Ramanan AV. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype. Pediatr Rheumatol Online J. 2020;18(1):37. https://doi.org/10.1186/s12969-020-00425-w.
Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Lewis JD, Ouellet-Hellstrom R, Patkar NM, Saag KG, Winthrop KL, Curtis JR, Collaboration SABER. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–80. https://doi.org/10.1002/art.34458.
Trachtman R, Murray E, Wang CM, Szymonifka J, Toussi SS, Walters H, Nellis ME, Onel KB, Mandl LA. Procalcitonin differs in children with infection and children with disease flares in juvenile idiopathic arthritis. J Clin Rheumatol. 2021;27(3):87–91. https://doi.org/10.1097/RHU.0000000000001170.
Poddighe D, Abdukhakimova D, Dossybayeva K, Mukusheva Z, Assylbekova M, Rakhimzhanova M, Ibrayeva A, Mukash G, Tuleutayev Y. Mycoplasma pneumoniae Seroprevalence and Total IgE Levels in Patients with Juvenile Idiopathic Arthritis. J Immunol Res. 2021;2021:6596596. https://doi.org/10.1155/2021/6596596.
Piotto D, Nicacio A, Neto A, Mourão AF, Oliveira-Ramos F, Campanilho-Marques R, Guedes M, Cabral M, Santos MJ, Fonseca JE, Canhão H, Aikawa NE, Oliveira SKF, Ferriani VPL, Pileggi GCS, Magalhães CS, Silva CA, Terreri MT. Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients. Adv Rheumatol (London, England). 2022;62(1):20. https://doi.org/10.1186/s42358-022-00251-6.
Fernández-Sarmiento J, De Souza D, Jabornisky R, Gonzalez GA, Arias López MDP, Palacio G. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. BMJ Paediatrics Open. 2021;5(1): e000894. https://doi.org/10.1136/bmjpo-2020-000894.
Haslak F, Ozbey D, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Guliyeva V, Yalcin G, Inanli G, Kocazeybek BS, Kasapcopur O, Barut K. Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children. Clin Rheumatol. 2022;41(5):1523–33. https://doi.org/10.1007/s10067-022-06067-5.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31(11):1409–17. https://doi.org/10.1007/s00296-011-1999-3.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research ed). 2009;339:b2700. https://doi.org/10.1136/bmj.b2700.
Kilinc AA, Arslan A, Yildiz M, Kucur M, Adrovic A, Barut K, Sahin S, Cokugras H, Kasapcopur O. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study. Rheumatol Int. 2020;40(10):1701–6. https://doi.org/10.1007/s00296-019-04485-4.
Iriguchi S, Kikuchi N, Kaneko S, Noguchi E, Morishima Y, Matsuyama M, Yoh K, Takahashi S, Nakauchi H, Ishii Y. T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung. Blood. 2015;125(2):370–82. https://doi.org/10.1182/blood-2014-05-575225.
Acknowledgements
The authors acknowledge Jianghong Deng, Weiying Kuang, Xiaohua Tan, Chao Li, Shipeng Li, for medical writing and editorial assistance based on the authors’ input and direction.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The Rapid Service Fee was funded by the authors.
Author Contributions
Cai-Feng Li. Literature search and data analysis: Feng-Qiao Gao. Draft writing: Feng-Qiao Gao and Jun-Mei Zhan. Critical revision and Supervision: Feng-Qiao Gao, Jun-Mei Zhan, and Cai-Feng Li. All authors accept responsibility for the accuracy and integrity of the final manuscript as submitted.
Disclosures
The authors Feng-Qiao Gao, Jun-Mei Zhan, and Cai-Feng Li have no connections or financial backings which have influenced or biased the content of this work.
Compliance with Ethics Guidelines
The authors declare that the contents of this article have not been previously published, either in whole or in part nor are currently under consideration for publication elsewhere. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Gao, FQ., Zhang, JM. & Li, CF. Clinical Presentation and Treatment of Juvenile Idiopathic Arthritis Combined with Lung Disease: A Narrative Review. Rheumatol Ther 10, 507–522 (2023). https://doi.org/10.1007/s40744-023-00542-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-023-00542-4